{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:44:43Z","timestamp":1789584283514,"version":"build-2803163510"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Biliary tract cancer (BTC) is an aggressive biliary tract cancer, arising from the bile ducts and gallbladder, with a poor prognosis. The TOPAZ-1 trial of durvalumab plus first-line chemotherapy (gemcitabine plus cisplatin) showed improved survival vs chemotherapy alone. This real-world study aimed to confirm the effectiveness of this regimen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective, multicenter study included patients with advanced BTC treated with first-line durvalumab plus platinum chemotherapy at the Linkou, Taoyuan, and Tucheng branches of Chang Gung Memorial Hospital as well as at Taipei Veterans General Hospital between August 2021 and June 2023.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among the 45 patients with advanced biliary tree cancer treated with durvalumab plus cisplatin and gemcitabine as first-line treatment, the objective response rate was 31.1% (14 partial responses). An additional 40% (18 patients) had stable disease. The median progression-free survival was 5.6 months (95%CI, 4.4-6.9) and median overall survival was 15.8 months (95%CI, 7.9-23.8). Responders had significantly longer survival than non-responders (15.8 vs 3.3 months). Although higher durvalumab doses (1000-1500\u00a0mg) appeared to have improved efficacy compared to lower doses (&amp;lt;1000\u00a0mg), the difference was not statistically significant. On multivariate analysis, poor ECOG performance status (\u22652) and a high neutrophil-lymphocyte ratio were independent prognostic factors for shorter overall survival.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This real-world study demonstrated the comparable efficacy of durvalumab plus chemotherapy to the TOPAZ-1 trial for patients with advanced BTC and identified prognostic factors. There was a trend toward improved efficacy with higher durvalumab dosing (1000-1500\u00a0mg) vs lower dosing, though further research is needed to confirm this relationship.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae306","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T16:52:47Z","timestamp":1732121567000},"source":"Crossref","is-referenced-by-count":11,"title":["Real-world effectiveness and prognostic factors of durvalumab plus chemotherapy in a multicentric cohort with advanced biliary tract cancer"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7789-8347","authenticated-orcid":false,"given":"Wen-Kuan","family":"Huang","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine , Taoyuan ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Jei","family":"Tang","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine , Taoyuan ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiao-En","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine , Taoyuan ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Mo","family":"Hou","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine , Taoyuan ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Chih","family":"Hsu","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine , Taoyuan ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Jung","family":"Su","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine , Taoyuan ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Jung","family":"Chiang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Taipei Veterans General Hospital , Taipei ,","place":["Taiwan"]},{"name":"School of Medicine, National Yang Ming Chiao Tung University , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"San-Chi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Taipei Veterans General Hospital , Taipei ,","place":["Taiwan"]},{"name":"School of Medicine, National Yang Ming Chiao Tung University , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Nan","family":"Yeh","sequence":"additional","affiliation":[{"name":"Department of General Surgery, GIST Team, and Liver Research Center, Chang Gung Memorial Hospital, Linkou Branch, Chang Gung University , Taoyuan ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Shi","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine , Taoyuan ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Huang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Taipei Veterans General Hospital , Taipei ,","place":["Taiwan"]},{"name":"School of Medicine, National Yang Ming Chiao Tung University , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hsun","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine , Taoyuan ,","place":["Taiwan"]},{"name":"Division of Hematology-Oncology, Department of Internal Medicine, New Taipei City Municipal Tucheng Hospital , New Taipei City ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chi","family":"Chou","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine , Taoyuan ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"2025082905265824900_CIT0001","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2025082905265824900_CIT0002","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1080\/0284186X.2017.1418532","article-title":"Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin","volume":"57","author":"Dierks","year":"2018","journal-title":"Acta Oncol"},{"key":"2025082905265824900_CIT0003","doi-asserted-by":"publisher","first-page":"100417","DOI":"10.1016\/j.jhepr.2021.100417","article-title":"Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer","volume":"4","author":"Thol","year":"2022","journal-title":"JHEP Rep"},{"key":"2025082905265824900_CIT0004","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med."},{"key":"2025082905265824900_CIT0005","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/liv.14098","article-title":"The tumour microenvironment and immune milieu of cholangiocarcinoma","volume":"39","author":"Fabris","year":"2019","journal-title":"Liver Int"},{"key":"2025082905265824900_CIT0006","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamaoncol.2020.0930","article-title":"A phase 2 Multi-institutional Study of nivolumab for patients with advanced refractory biliary tract cancer","volume":"6","author":"Kim","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025082905265824900_CIT0007","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1002\/cam4.4593","article-title":"Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer","volume":"11","author":"Doki","year":"2022","journal-title":"Cancer Med"},{"key":"2025082905265824900_CIT0008","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"Int J Cancer"},{"key":"2025082905265824900_CIT0009","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","article-title":"Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study","volume":"7","author":"Oh","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025082905265824900_CIT0010","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with ad-vanced biliary tract cancer (BTC): TOPAZ-1","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"2025082905265824900_CIT0011","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1002\/sim.4780141906","article-title":"The restricted cubic spline as baseline hazard in the proportional hazards model with step function time-dependent covariables","volume":"14","author":"Herndon","year":"1995","journal-title":"Stat Med"},{"key":"2025082905265824900_CIT0012","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"2025082905265824900_CIT0013","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1111\/liv.15641","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: an early exploratory analysis of real-world data","volume":"43","author":"Rimini","year":"2023","journal-title":"Liver Int"},{"key":"2025082905265824900_CIT0014","doi-asserted-by":"publisher","first-page":"110344","DOI":"10.1016\/j.intimp.2023.110344","article-title":"First-line PD-1 inhibitors combination therapy for patients with advanced cholangiocarcinoma: a retrospective real-world study","volume":"120","author":"Ye","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"2025082905265824900_CIT0015","doi-asserted-by":"publisher","first-page":"e000332","DOI":"10.1136\/esmoopen-2018-000332","article-title":"Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity","volume":"3","author":"Yoo","year":"2018","journal-title":"ESMO Open"},{"key":"2025082905265824900_CIT0016","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1186\/s12885-022-10271-6","article-title":"Low-dose nivolumab in advanced hepatocellular carcinoma","volume":"22","author":"Chen","year":"2022","journal-title":"BMC Cancer."},{"key":"2025082905265824900_CIT0017","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1159\/000512000","article-title":"Low-dose nivolumab in renal cell carcinoma: a real-world experience","volume":"99","author":"Zhao","year":"2021","journal-title":"Oncology (Huntingt)"},{"key":"2025082905265824900_CIT0018","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jfma.2023.09.020","article-title":"Real-world efficacy and safety of low-dose pembrolizumab in patients with advanced and refractory gynecologic cancers","volume":"123","author":"Kao","year":"2023","journal-title":"J Formos Med Assoc"},{"key":"2025082905265824900_CIT0019","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1002\/cncr.34348","article-title":"Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: a post hoc analysis of the phase 3 OAK trial","volume":"128","author":"Cortellini","year":"2022","journal-title":"Cancer"},{"key":"2025082905265824900_CIT0020","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/apt.17441","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: results from a German real-world cohort","volume":"57","author":"Jost-Brinkmann","year":"2023","journal-title":"Aliment Pharmacol Ther"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/8\/oyae306\/60773320\/oyae306.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/8\/oyae306\/60773320\/oyae306.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T09:27:01Z","timestamp":1756459621000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae306\/7905746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae306","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2024,11,20]]},"article-number":"oyae306"}}